indomethacin has been researched along with Uterine Neoplasms in 8 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Uterine Neoplasms: Tumors or cancer of the UTERUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We retrospectively reviewed seven cases of degenerating fibroids complicating pregnancy where the prostaglandin synthetase inhibitor, indomethacin (25 mg orally every 6 hours), was used to treat symptoms of pain." | 7.68 | Indomethacin for the treatment of symptomatic leiomyoma uteri during pregnancy. ( Carpenter, RJ; Dildy, GA; Kirshon, B; Moise, KJ; Smith, LG, 1992) |
| " We retrospectively reviewed seven cases of degenerating fibroids complicating pregnancy where the prostaglandin synthetase inhibitor, indomethacin (25 mg orally every 6 hours), was used to treat symptoms of pain." | 3.68 | Indomethacin for the treatment of symptomatic leiomyoma uteri during pregnancy. ( Carpenter, RJ; Dildy, GA; Kirshon, B; Moise, KJ; Smith, LG, 1992) |
| "Indomethacin, a prostaglandin synthetase inhibitor given to 94 women suffering from functional menorrhagia, IUD's and sub mucous fibroid related bleeding, reduced menstrual loss and duration of menstruation in 70 patients (74." | 3.67 | The effect of a prostaglandin synthetase inhibitor, indomethacin, on excessive uterine bleeding. ( Anteby, SO; Ever Hadani, P; Yarkoni, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Margolick, J | 1 |
| Bonomi, P | 1 |
| Fordham, E | 1 |
| Yordan, E | 1 |
| Slayton, R | 1 |
| Wilbanks, G | 1 |
| Johnsrud, ML | 1 |
| Virdis, A | 1 |
| Ghiadoni, L | 1 |
| Pinto, S | 1 |
| Lombardo, M | 1 |
| Petraglia, F | 1 |
| Gennazzani, A | 1 |
| Buralli, S | 1 |
| Taddei, S | 1 |
| Salvetti, A | 1 |
| Dildy, GA | 1 |
| Moise, KJ | 1 |
| Smith, LG | 1 |
| Kirshon, B | 1 |
| Carpenter, RJ | 1 |
| Kuo, TM | 1 |
| Taketani, Y | 1 |
| Ayabe, T | 1 |
| Gomibuchi, H | 1 |
| Yano, T | 1 |
| Tsutsumi, O | 1 |
| Mizuno, M | 1 |
| Ilekis, J | 1 |
| Benveniste, R | 1 |
| Yron, I | 1 |
| Schickler, M | 1 |
| Fisch, B | 1 |
| Pinkas, H | 1 |
| Ovadia, J | 1 |
| Witz, IP | 1 |
| Anteby, SO | 1 |
| Yarkoni, S | 1 |
| Ever Hadani, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency[NCT00608062] | 155 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Carotid artery compliance measured by carotid artery ultrasound and brachial artery blood pressure (NCT00608062)
Timeframe: Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment
| Intervention | mm2/mm Hg×10-1 (Mean) | ||
|---|---|---|---|
| Baseline | GnRHant alone | GnRHant + Add-Back | |
| Peri1 | 0.90 | 0.89 | 0.98 |
| Peri2 | 1.02 | 0.94 | 0.94 |
| Post1 | 0.89 | 0.85 | 0.92 |
| Post2 | 0.74 | 0.79 | 0.80 |
| Pre1 | 1.31 | 1.27 | 1.29 |
| Pre2 | 1.34 | 1.19 | 1.14 |
"Brachial artery flow-mediated dilation (FMD) assessed by ultrasound. This other outcome measure was originally specified as Secondary in error and has been updated to Primary to be consistent with the protocol." (NCT00608062)
Timeframe: Baseline, day 4 of GnRHant and Day 7 of GnRHant and estradiol or placebo treatment
| Intervention | % Diameter Change (Mean) | |||
|---|---|---|---|---|
| Baseline | Day 4 of GnRHant alone | Day 7 of GnRHant plus treatment | Acute Vitamin C Infusion Day 7 | |
| Peri1 | 7.7 | 5.8 | 9.6 | 9.3 |
| Peri2 | 6.1 | 6.6 | 6.1 | 11.2 |
| Post1 | 5.4 | 4.9 | 8.4 | 7.8 |
| Post2 | 5.3 | 4.9 | 4.2 | 6.7 |
| Pre1 | 9.8 | 7.1 | 10.6 | 8.4 |
| Pre2 | 11.3 | 8.9 | 7.8 | 11.2 |
"This other outcome measure was originally specified as Secondary in error and has been updated to Other, Pre-specified to be consistent with the protocol." (NCT00608062)
Timeframe: Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back
| Intervention | pg/mL (Mean) | ||
|---|---|---|---|
| Baseline | GnRHant alone | GnRhant+Add-back | |
| Peri1 | 5.9 | 6.0 | 5.9 |
| Peri2 | 6.2 | 5.9 | 5.7 |
| Post1 | 6.2 | 6.5 | 6.0 |
| Post2 | 6.4 | 6.5 | 6.4 |
| Pre1 | 5.2 | 5.5 | 6.0 |
| Pre2 | 5.2 | 5.5 | 5.0 |
"This other outcome measure was originally specified as Secondary in error and has been updated to Other, Pre-specified to be consistent with the protocol. Serum estradiol for clinical characteristics and to detect changes in estradiol levels with the interventions." (NCT00608062)
Timeframe: Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment
| Intervention | pmol/L (Median) | ||
|---|---|---|---|
| Baseline | GnRHant alone | GnRhant+Add-back | |
| Peri1 | 360 | 92 | 187 |
| Peri2 | 147 | 99 | 106 |
| Post1 | 39 | 37 | 165 |
| Post2 | 37 | 37 | 37 |
| Pre1 | 229 | 147 | 202 |
| Pre2 | 270 | 127 | 134 |
"This other outcome measure was originally specified as Secondary in error and has been updated to Other, Pre-specified to be consistent with the protocol." (NCT00608062)
Timeframe: Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| Baseline | GnRHant alone | GnRhant+Add-back | |
| Peri1 | 227 | 235 | 231 |
| Peri2 | 247 | 233 | 217 |
| Post1 | 231 | 280 | 204 |
| Post2 | 242 | 217 | 221 |
| Pre1 | 161 | 144 | 146 |
| Pre2 | 184 | 156 | 217 |
"This other outcome measure was originally specified as Secondary in error and has been updated to Other, Pre-specified to be consistent with the protocol. Serum progesterone was measured for clinical characteristics and to determine changes in sex hormones." (NCT00608062)
Timeframe: Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back
| Intervention | nmol/L (Median) | ||
|---|---|---|---|
| Baseline | GnRHant alone | GnRhant+Add-back | |
| Peri1 | 1.1 | 1.0 | 0.8 |
| Peri2 | 1.3 | 1.0 | 1.6 |
| Post1 | 1.1 | 1.0 | 1.0 |
| Post2 | 0.9 | 0.6 | 0.6 |
| Pre1 | 1.8 | 1.3 | 1.0 |
| Pre2 | 2.1 | 1.7 | 1.0 |
(NCT00608062)
Timeframe: Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Baseline | Day 4 of GnRHant alone | Day 7 of GnRHant plus treatment | |
| Peri1 | 111 | 112 | 108 |
| Peri2 | 109 | 108 | 109 |
| Post1 | 117 | 116 | 112 |
| Post2 | 123 | 115 | 111 |
| Pre1 | 102 | 107 | 103 |
| Pre2 | 108 | 111 | 110 |
"This other outcome measure was originally specified as Secondary in error and has been updated to Other, Pre-specified to be consistent with the protocol. TAS is an antioxidant and is a biomarker of oxidative stress." (NCT00608062)
Timeframe: Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back
| Intervention | nmol/L (Mean) | ||
|---|---|---|---|
| Baseline | GnRHant alone | GnRhant+Add-back | |
| Peri1 | 1.3 | 1.3 | 1.3 |
| Peri2 | 1.3 | 1.3 | 1.3 |
| Post1 | 1.3 | 1.3 | 1.3 |
| Post2 | 1.3 | 1.4 | 1.3 |
| Pre1 | 1.4 | 1.4 | 1.4 |
| Pre2 | 1.4 | 1.5 | 1.4 |
8 other studies available for indomethacin and Uterine Neoplasms
| Article | Year |
|---|---|
Hypertrophic osteoarthropathy associated with endometrial carcinoma.
Topics: Aged; Bone and Bones; Female; Humans; Indomethacin; Lung Neoplasms; Osteoarthropathy, Secondary Hype | 1982 |
Successful pregnancy outcome in uterus didelphys with leiomyoma uteri.
Topics: Adult; Bed Rest; Cesarean Section; Female; Humans; Indomethacin; Leiomyoma; Obstetric Labor, Prematu | 1994 |
Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women.
Topics: Acetylcholine; Adult; Arginine; Ascorbic Acid; Blood Pressure; Cardiovascular Agents; Endothelium, V | 2000 |
Indomethacin for the treatment of symptomatic leiomyoma uteri during pregnancy.
Topics: Adult; Drug Administration Schedule; Female; Humans; Indomethacin; Leiomyoma; Palliative Care; Pregn | 1992 |
[Influence of peritoneal fluid with endometriosis on the development of mouse embryos].
Topics: Animals; Ascitic Fluid; Dinoprostone; Embryonic and Fetal Development; Endometriosis; Female; Humans | 1990 |
Effects of epidermal growth factor, phorbol myristate acetate, and arachidonic acid on choriogonadotropin secretion by cultured human choriocarcinoma cells.
Topics: Arachidonic Acid; Arachidonic Acids; Caenorhabditis elegans Proteins; Carrier Proteins; Catechols; C | 1985 |
The immune system during the pre-cancer and the early cancer period. IL-2 production by PBL from post-menopausal women with and without endometrial carcinoma.
Topics: B-Lymphocytes; Carcinoma; Female; Humans; Indomethacin; Interleukin-2; Lymphocyte Activation; Macrop | 1986 |
The effect of a prostaglandin synthetase inhibitor, indomethacin, on excessive uterine bleeding.
Topics: Adult; Drug Evaluation; Female; Humans; Indomethacin; Intrauterine Devices; Leiomyoma; Menorrhagia; | 1985 |